About this study:
Agitation is a common and serious problem among people living with Alzheimer’s dementia. This Aspect® clinical study involves researchers who want to find out if an investigational drug, AVP-786, is safe and effective (useful) in managing agitation in adults with Alzheimer’s dementia, when compared to a placebo. Examples of agitated behaviors include:
- Pacing/aimless wandering
- Hitting others or self
- Throwing things
- Pushing people
- Hurting self or others
- Constant unwarranted requests for attention or help
- Tearing things or destroying property
Who can participate in this study:
Potential participants must be:
- Between the ages of 50 and 90
- Have a diagnosis of probable Alzheimer’s disease
- Have moderate-to-severe agitation that interferes with daily life
- Have a caregiver who spends a minimum of two hours per day, four days per week with them and is willing and able to comply with all the study procedures
There may be additional requirements discussed with the doctor.
What are my costs to take part in this trial?
All tests and procedures that are part of the study, and the study visits are provided at no charge to you or your insurance company.
How to get started?
Step 1: Contact our study coordinator, and he/she will give you information and help determine if you qualify.
Step 2: Give informed consent. A study doctor will explain the procedures and possible benefits and risks. The study doctor will also answer any questions you may have about the Aspect® study. To join our study, you must read and sign an informed consent document to show that you understand the study and what is required of you.
Step 3: Find out if you are eligible. The study staff will ask some health questions and may do a medical evaluation to see if you meet the requirements.